Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma; Results from Phase 1b/2 CARTITUDE-1 to premiere in oral presentation at the American Socie

Press/Media

Period7 Dec 2019

Media coverage

3

Media coverage

  • TitleJanssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma; Results from Phase 1b/2 CARTITUDE-1 to premiere in oral presentation at the American Socie
    Media name/outletBusiness Wire
    Country/TerritoryUnited States
    Date7/12/19
    PersonsDeepu Madduri
  • TitleJanssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma; Results from Phase 1b/2 CARTITUDE-1 to premiere in oral presentation at the American Socie
    Media name/outletBusiness Wire
    Country/TerritoryUnited States
    Date7/12/19
    PersonsDeepu Madduri
  • TitleJanssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma; Results from Phase 1b/2 CARTITUDE-1 to premiere in oral presentation at the American Socie
    Media name/outletBusiness Wire
    Country/TerritoryUnited States
    Date7/12/19
    PersonsDeepu Madduri